Latest news with #Exicure
Business Wire
2 days ago
- Business
- Business Wire
Exicure, Inc. Reports Second Quarter 2025 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the 'Company') releases the following financial results for the fiscal quarter ended June 30, 2025. Second Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $7.9 million as of June 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended June 30, 2025, as compared to $0 for the quarter ended June 30, 2024. The increase in R&D expense of $0.9 million for the three months ended June 30, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ('GPCR USA'), which is conducting research. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses. General and Administrative (G&A) Expense: General and administrative expenses were $1.5 million for the quarter ended June 30, 2025, as compared to $1.2 million for the quarter ended June 30, 2024. The increase in G&A expense of $0.3 million for the three months ended June 30, 2025 was mostly due to the additional expenses incurred from the acquisition of GPCR USA and increased professional services compared to the same prior year quarter. Loss from sale or disposal of property and equipment: The Company recognized a $60,000 loss from GPCR USA's sale of fixed assets. Other Income and Expense: The Company recognized a loss of $159,000 related to the change in the fair value of its contingent liability. Net Income (Loss): The Company had a net loss of $2.6 million for the quarter ended June 30, 2025, as compared to a net loss of $0.6 million for the quarter ended June 30, 2024. The increase in net loss of $2 million was primarily due to the increased operating expenses from the acquisition of GPCR USA. Going Concern: Management believes that the Company's existing cash and cash equivalents is not sufficient to continue to fund operations. The Company has already engaged in significant cost reductions, and our ability to further cut costs and extend the Company's operating runway is limited. As a result, substantial additional financing is needed in the short term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. The Company also needs to raise capital to fund its operations. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms. About Exicure, Inc. Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company's lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company's current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value, the timing of the equity investment closing and potential additional equity investment and the Nasdaq Hearings Panel process and potential results. Words such as 'plans,' 'expects,' 'will,' 'anticipates,' 'continue,' 'advance,' 'believes,' 'target,' 'may,' 'intend,' 'could,' and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management's current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 18, 2025, as updated by the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law. June 30, 2 025 2 024 ASSETS Current assets: Cash and cash equivalents $ 7,858 $ 12,508 Other receivable 77 521 Prepaid expenses and other current assets 711 644 Total current assets 8,646 13,673 Other noncurrent assets 1,992 1,357 Property and equipment, net 712 26 Right-of-use asset, net 264 — Intangible asset 3,784 — Goodwill 3,340 — Total assets $ 18,738 $ 15,056 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,838 $ 1,031 Accrued expenses and other current liabilities 2,731 2,040 Total current liabilities 4,569 3,071 Lease liability, noncurrent — 5,213 Contingent consideration 5,306 — Total liabilities 9,875 8,284 Commitments and Contingencies (Note 12) Stockholders' equity: Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, June 30, 2025 and December 31, 2024 — — Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 6,317,793 issued and outstanding, June 30, 2025; 6,026,841 issued and outstanding, December 31, 2024 1 1 Additional paid-in capital 207,636 206,035 Accumulated other comprehensive income 101 — Accumulated deficit (198,875 ) (199,264 ) Total stockholders' equity 8,863 6,772 Total liabilities and stockholders' equity $ 18,738 $ 15,056 Expand Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue: Revenue $ — $ — $ — $ 500 Total revenue — — — 500 Operating expenses: Research and development expense 935 — 1,743 — General and administrative expense 1,514 1,235 3,731 2,571 Loss from sale or disposal of property and equipment 60 — 86 — Gain on early lease termination — — (5,974 ) — Total operating expenses 2,509 1,235 (414 ) 2,571 Operating income (loss) (2,509 ) (1,235 ) 414 (2,071 ) Other income (expense), net: Dividend income 52 1 79 5 Interest income 4 3 9 6 Gain on settlement of accounts payables — — 191 — Change in fair value of contingent liability (159 ) — (295 ) — Other expense, net (9 ) 631 (9 ) 631 Total other income, net (112 ) 635 (25 ) 642 Net income (loss) before provision for income taxes (2,621 ) (600 ) 389 (1,429 ) Provision for income taxes — — — — Net income (loss) $ (2,621 ) $ (600 ) $ 389 $ (1,429 ) Net income (loss) per common share: * Basic $ (0.41 ) $ (0.35 ) $ 0.06 $ (0.83 ) Diluted $ (0.41 ) $ (0.35 ) $ 0.06 $ (0.83 ) Weighted-average common shares outstanding: * reflects a one-for-five (1:5) reverse stock split effected on August 27, 2024 Expand
Business Wire
6 days ago
- Business
- Business Wire
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. ('Exicure' or the 'Company') (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company regained compliance with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the 'Rule') based on the filing of its periodic reports on Form 10-Q to the United States Securities and Exchange Commission for the fiscal quarter ended March 31, 2025. The Company has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq') confirming compliance with the Rule and stating that the matter has been resolved. About Exicure Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see
Business Wire
01-08-2025
- Business
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
Business Wire
27-06-2025
- Business
- Business Wire
Exicure, Inc. Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the 'Company') releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ('GPCR USA'), which is conducting research. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses. General and Administrative (G&A) Expense: General and administrative expenses were $2.2 million for the quarter ended March 31, 2025, as compared to $1.3 million for the quarter ended March 31, 2024. The increase in G&A expense of $0.9 million for the three months ended March 31, 2025 was mostly due to the additional expenses incurred from the acquisition of GPCR USA and increased professional services compared to the same prior year quarter. Gain on early lease termination: Due to the early termination of the Chicago lease as of January 31, 2025, the Company recognized a $6 million gain resulting from the reversal of the remaining liability related to this lease. Other Income: The Company recognized a gain from the reversal of liability related to registration rights delay amounts owed to a shareholder after they agreed to waive the penalty amount owed. Net Income (Loss): The Company had a net income of $3.0 million for the quarter ended March 31, 2025, as compared to a net loss of $0.8 million for the quarter ended March 31, 2024. The increase in net income of $3.8 million was primarily driven by the $6 million gain from the reversal of the lease liability, offset by increased operating expenses from the acquisition of GPCR USA. Going Concern: Management believes that the Company's existing cash and cash equivalents is not sufficient to continue to fund operations. The Company has already engaged in significant cost reductions, and our ability to further cut costs and extend the Company's operating runway is limited. As a result, substantial additional financing is needed in the short term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. The Company also needs to raise capital to fund its operations. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms. About Exicure, Inc. Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company's lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company's current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value, the timing of the equity investment closing and potential additional equity investment and the Nasdaq Hearings Panel process and potential results. Words such as 'plans,' 'expects,' 'will,' 'anticipates,' 'continue,' 'advance,' 'believes,' 'target,' 'may,' 'intend,' 'could,' and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management's current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 18, 2025, as updated by the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law. (in thousands, except share and per share data) March 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 10,420 $ 12,508 Other receivable 172 521 Prepaid expenses and other current assets 713 644 Total current assets 11,305 13,673 Other noncurrent assets 1,449 1,357 Property and equipment, net 565 26 Right-of-use asset 237 — Intangible Asset 3,784 — Goodwill 3,340 — Total assets $ 20,680 $ 15,056 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,210 $ 1,031 Accrued expenses and other current liabilities 2,679 2,040 Total current liabilities 3,889 3,071 Lease liability, noncurrent 27 5,213 Contingent Consideration 5,382 — Total liabilities 9,298 8,284 Commitments and Contingencies (Note 14) Stockholders' equity: Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, March 31, 2025 and December 31, 2024 — — Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 6,317,771 issued and outstanding, March 31, 2025; 6,026,841 issued and outstanding, December 31, 2024 1 1 Additional paid-in capital 207,635 206,035 Accumulated deficit (196,254 ) (199,264 ) Total stockholders' equity 11,382 6,772 Total liabilities and stockholders' equity $ 20,680 $ 15,056 Expand EXICURE, INC. (in thousands, except share and per share data) Three Months Ended March 31, 2025 2024 Revenue: Revenue $ — $ 500 Total revenue — 500 Operating expenses: Research and development expense 808 — General and administrative expense 2,217 1,336 Gain on early lease termination (5,974 ) — Total operating expenses (2,949 ) 1,336 Operating income (loss) 2,949 (836 ) Other income (expense), net: Dividend income 27 4 Interest income 5 3 Gain on settlement of accounts payables 191 — Change in fair value of contingent liability (136 ) — Other expense, net (26 ) — Total other income, net 61 7 Net income (loss) before provision for income taxes 3,010 (829 ) Provision for income taxes — — Net income (loss) $ 3,010 $ (829 ) Net income (loss) per common share: * Basic $ 0.49 $ (0.48 ) Diluted $ 0.49 $ (0.48 ) Weighted-average common shares outstanding: Basic 6,172,268 1,730,201 * reflects a one-for-five (1:5) reverse stock split effected on August 27, 2024 Expand
Business Insider
29-05-2025
- Business
- Business Insider
Exicure receives Nasdaq delinquency notice on late Form 10-Q filing
Exicure (XCUR) announced it received a notice of non-compliance from Nasdaq on May 21. The notice stated the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31. Exicure has 60 days to submit a plan to regain compliance. If accepted, the company could be granted up to 180 days from the Form 10-Q due date, or until November 17, to regain compliance. Confident Investing Starts Here:
